P3781
Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinA Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and ExerciseBioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-AdministeredBioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy ParticipantsEffects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes MellitusEffect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte InflammationEffects of DPP-4 Inhibition on TriglyceridesStudy of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DMSaxagliptin and AtherosclerosisDescription of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in FranceACute and Chronic Effects of SaxagliptinStudy in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin ProducBioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-BrazilEffects of Saxagliptin on Endothelial FunctionNeuropeptide Y and Sympathovagal BalanceStudy of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic TherapyReplication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
P4844
Saxagliptin overview: special focus on safety and adverse effectsSaxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataDevelopment of a rapid UPLC-MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.Metformin + saxagliptin for type 2 diabetes.Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Pharmacokinetic study of saxagliptin in healthy Chinese subjects.Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in SwedenThe cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in PolandLiquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific b
P921
Q61907055-5EDD5F9C-44C5-4322-8ED9-7B1B3F2C91E2Q61932452-45CD0CDD-C1D6-4FB7-B65E-01B8213D5A93Q61939004-ACDD774D-0387-4F52-83F0-851101AD7BC5Q61939009-5493E05A-6DFF-4D8B-96A4-9E47852277DCQ62041192-E369A1FE-DC7D-4D77-97E2-1CB96D3BABF9Q62062362-C165679C-56D2-43B4-89B1-09224A975AC7Q63316344-C0938A34-8E02-41E3-87AE-48CD83633223Q63318087-96C0D61E-1D08-4CC5-9FF4-49577F95C8A8Q63319006-CB5FABE2-0494-4887-9499-88B488D2D9BBQ63319671-D9A75A6E-C842-419C-BB15-BF8A847BD92EQ63319675-5E2819B8-34AD-4663-9532-F0889267B8AEQ63320120-340FD9EC-9FC9-4EBC-82D2-F0F184847076Q63322260-9571D8EA-9C1A-47C1-9683-E5B3AB9FA96AQ63333945-8D0E5C2D-F0AD-4BBB-87E1-610922C62F89Q63336994-DCF82FAB-2B19-4292-9F82-7CE7CC843442Q63576216-4B32BA57-DDB1-4DE7-B518-92C1F01E8198Q63597054-9B527ED6-E450-458F-A6AD-C1BE76219159Q63805249-21B2229F-D69A-4F56-B91F-9562779A8B87
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Saksagliptin
@sh
Saksagliptin
@sr
Saptagliptina
@es
Saxagliptin
@de
saksagliptyna
@pl
saxagliptin
@en
saxagliptina
@pt
saxagliptine
@fr
סאקסאגליפטין
@he
沙格列汀
@zh
type
label
Saksagliptin
@sh
Saksagliptin
@sr
Saptagliptina
@es
Saxagliptin
@de
saksagliptyna
@pl
saxagliptin
@en
saxagliptina
@pt
saxagliptine
@fr
סאקסאגליפטין
@he
沙格列汀
@zh
altLabel
(1S,3S,5S)-2-((2S)-Amino(3-hyd ...... lo(3.1.0)hexane-3-carbonitrile
@en
361442-04-8
@fr
BMS 477118
@en
BMS-477118
@en
C18H25N3O2
@fr
Onglyza
@pt
SAXAGLIPTIN
@en
Saxagliptin anhydrous
@en
Saxagliptin
@en
Saxagliptina
@es
prefLabel
Saksagliptin
@sh
Saksagliptin
@sr
Saptagliptina
@es
Saxagliptin
@de
saksagliptyna
@pl
saxagliptin
@en
saxagliptina
@pt
saxagliptine
@fr
סאקסאגליפטין
@he
沙格列汀
@zh
P592
P6366
P646
P661
P662
P665
P683
P1579
P2017
C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N
P2057
HMDB0015634
P2067
315.194677